Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LPAD Approval Pathway Is Not Saving Antimicrobial Development

Executive Summary

US FDA and CMS explore reimbursement ideas to strengthen business case for antimicrobial development; new approval pathway likely is only needed in special situations.
Advertisement

Related Content

A Call To Action On Antibiotic Development
LPAD As An Afterthought? Insmed’s Arikayce Reaches US Market Thanks To Limited Population Pathway
BARDA Official Worries About How Non-Traditional Antibiotics Will Get To Market
Antibiotic Guidance: Limited Populations Do Not Include Rare Infections
Gottlieb Floats New Antibiotic Payment Model In LPAD Announcement
US FDA Joins Chorus Of Concerns About Results Of GAIN Act
Best Of BIO: Policy & Regulatory Updates From BIO 2017
FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway
Orphan Antibiotics? Woodcock Says It May Be Possible If IDSA’s New Pathway Is Implemented

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124302

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel